Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
VIO-01 in Metastatic Solid Tumor: NCT06257758 Clinical Landscape Report 2026
16 October 2026
NCT06257758 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cisplatin/Vinblastine/SHAO in Metastatic Soft Tissue Sarcoma: NCT06263231 Clinical Landscape Report 2026
16 October 2026
NCT06263231 clinical landscape for Metastatic Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Oesophageal squamous cell carcinoma recurrent: NCT06265285 Clinical Landscape Report 2026
16 October 2026
NCT06265285 clinical landscape for Oesophageal squamous cell carcinoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and developme…
9 min read
Golcadomide Hydrochloride in Refractory High-Grade B-Cell Lymphoma: NCT06271057 Clinical Landscape Report 2026
16 October 2026
NCT06271057 clinical landscape for Refractory High-Grade B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
ARTS-876 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
ARTS-876: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Influenza A virus H7N9 vaccine nanopatch (Vaxxas) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Influenza A virus H7N9 vaccine nanopatch (Vaxxas): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, marke
9 min read
BRE-AD01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
BRE-AD01: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Ad-hCMV-Flt3L(University of Michigan Rogel Cancer Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Ad-hCMV-Flt3L(University of Michigan Rogel Cancer Center): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deal
9 min read
TJ-064 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
TJ-064: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
KA-34 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
KA-34: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
KK-3910 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
KK-3910: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
A-002 (eTheRNA) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
A-002 (eTheRNA): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.